Cargando…

Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials

BACKGROUND AND OBJECTIVE: Dysferlinopathies are a group of muscle disorders caused by mutations in the DYSF gene. Previous muscle imaging studies describe a selective pattern of muscle involvement in smaller patient cohorts, but a large imaging study across the entire spectrum of the dysferlinopathi...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz-Manera, Jordi, Fernandez-Torron, Roberto, LLauger, Jaume, James, Meredith K, Mayhew, Anna, Smith, Fiona E, Moore, Ursula R, Blamire, Andrew M, Carlier, Pierre G, Rufibach, Laura, Mittal, Plavi, Eagle, Michelle, Jacobs, Marni, Hodgson, Tim, Wallace, Dorothy, Ward, Louise, Smith, Mark, Stramare, Roberto, Rampado, Alessandro, Sato, Noriko, Tamaru, Takeshi, Harwick, Bruce, Rico Gala, Susana, Turk, Suna, Coppenrath, Eva M, Foster, Glenn, Bendahan, David, Le Fur, Yann, Fricke, Stanley T, Otero, Hansel, Foster, Sheryl L, Peduto, Anthony, Sawyer, Anne Marie, Hilsden, Heather, Lochmuller, Hanns, Grieben, Ulrike, Spuler, Simone, Tesi Rocha, Carolina, Day, John W, Jones, Kristi J, Bharucha-Goebel, Diana X, Salort-Campana, Emmanuelle, Harms, Matthew, Pestronk, Alan, Krause, Sabine, Schreiber-Katz, Olivia, Walter, Maggie C, Paradas, Carmen, Hogrel, Jean-Yves, Stojkovic, Tanya, Takeda, Shin’ichi, Mori-Yoshimura, Madoka, Bravver, Elena, Sparks, Susan, Bello, Luca, Semplicini, Claudio, Pegoraro, Elena, Mendell, Jerry R, Bushby, Kate, Straub, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166612/
https://www.ncbi.nlm.nih.gov/pubmed/29735511
http://dx.doi.org/10.1136/jnnp-2017-317488
_version_ 1783360073091776512
author Diaz-Manera, Jordi
Fernandez-Torron, Roberto
LLauger, Jaume
James, Meredith K
Mayhew, Anna
Smith, Fiona E
Moore, Ursula R
Blamire, Andrew M
Carlier, Pierre G
Rufibach, Laura
Mittal, Plavi
Eagle, Michelle
Jacobs, Marni
Hodgson, Tim
Wallace, Dorothy
Ward, Louise
Smith, Mark
Stramare, Roberto
Rampado, Alessandro
Sato, Noriko
Tamaru, Takeshi
Harwick, Bruce
Rico Gala, Susana
Turk, Suna
Coppenrath, Eva M
Foster, Glenn
Bendahan, David
Le Fur, Yann
Fricke, Stanley T
Otero, Hansel
Foster, Sheryl L
Peduto, Anthony
Sawyer, Anne Marie
Hilsden, Heather
Lochmuller, Hanns
Grieben, Ulrike
Spuler, Simone
Tesi Rocha, Carolina
Day, John W
Jones, Kristi J
Bharucha-Goebel, Diana X
Salort-Campana, Emmanuelle
Harms, Matthew
Pestronk, Alan
Krause, Sabine
Schreiber-Katz, Olivia
Walter, Maggie C
Paradas, Carmen
Hogrel, Jean-Yves
Stojkovic, Tanya
Takeda, Shin’ichi
Mori-Yoshimura, Madoka
Bravver, Elena
Sparks, Susan
Bello, Luca
Semplicini, Claudio
Pegoraro, Elena
Mendell, Jerry R
Bushby, Kate
Straub, Volker
author_facet Diaz-Manera, Jordi
Fernandez-Torron, Roberto
LLauger, Jaume
James, Meredith K
Mayhew, Anna
Smith, Fiona E
Moore, Ursula R
Blamire, Andrew M
Carlier, Pierre G
Rufibach, Laura
Mittal, Plavi
Eagle, Michelle
Jacobs, Marni
Hodgson, Tim
Wallace, Dorothy
Ward, Louise
Smith, Mark
Stramare, Roberto
Rampado, Alessandro
Sato, Noriko
Tamaru, Takeshi
Harwick, Bruce
Rico Gala, Susana
Turk, Suna
Coppenrath, Eva M
Foster, Glenn
Bendahan, David
Le Fur, Yann
Fricke, Stanley T
Otero, Hansel
Foster, Sheryl L
Peduto, Anthony
Sawyer, Anne Marie
Hilsden, Heather
Lochmuller, Hanns
Grieben, Ulrike
Spuler, Simone
Tesi Rocha, Carolina
Day, John W
Jones, Kristi J
Bharucha-Goebel, Diana X
Salort-Campana, Emmanuelle
Harms, Matthew
Pestronk, Alan
Krause, Sabine
Schreiber-Katz, Olivia
Walter, Maggie C
Paradas, Carmen
Hogrel, Jean-Yves
Stojkovic, Tanya
Takeda, Shin’ichi
Mori-Yoshimura, Madoka
Bravver, Elena
Sparks, Susan
Bello, Luca
Semplicini, Claudio
Pegoraro, Elena
Mendell, Jerry R
Bushby, Kate
Straub, Volker
author_sort Diaz-Manera, Jordi
collection PubMed
description BACKGROUND AND OBJECTIVE: Dysferlinopathies are a group of muscle disorders caused by mutations in the DYSF gene. Previous muscle imaging studies describe a selective pattern of muscle involvement in smaller patient cohorts, but a large imaging study across the entire spectrum of the dysferlinopathies had not been performed and previous imaging findings were not correlated with functional tests. METHODS: We present cross-sectional T1-weighted muscle MRI data from 182 patients with genetically confirmed dysferlinopathies. We have analysed the pattern of muscles involved in the disease using hierarchical analysis and presented it as heatmaps. Results of the MRI scans have been correlated with relevant functional tests for each region of the body analysed. RESULTS: In 181 of the 182 patients scanned, we observed muscle pathology on T1-weighted images, with the gastrocnemius medialis and the soleus being the most commonly affected muscles. A similar pattern of involvement was identified in most patients regardless of their clinical presentation. Increased muscle pathology on MRI correlated positively with disease duration and functional impairment. CONCLUSIONS: The information generated by this study is of high diagnostic value and important for clinical trial development. We have been able to describe a pattern that can be considered as characteristic of dysferlinopathy. We have defined the natural history of the disease from a radiological point of view. These results enabled the identification of the most relevant regions of interest for quantitative MRI in longitudinal studies, such as clinical trials. CLINICAL TRIAL REGISTRATION: NCT01676077.
format Online
Article
Text
id pubmed-6166612
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-61666122018-10-04 Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials Diaz-Manera, Jordi Fernandez-Torron, Roberto LLauger, Jaume James, Meredith K Mayhew, Anna Smith, Fiona E Moore, Ursula R Blamire, Andrew M Carlier, Pierre G Rufibach, Laura Mittal, Plavi Eagle, Michelle Jacobs, Marni Hodgson, Tim Wallace, Dorothy Ward, Louise Smith, Mark Stramare, Roberto Rampado, Alessandro Sato, Noriko Tamaru, Takeshi Harwick, Bruce Rico Gala, Susana Turk, Suna Coppenrath, Eva M Foster, Glenn Bendahan, David Le Fur, Yann Fricke, Stanley T Otero, Hansel Foster, Sheryl L Peduto, Anthony Sawyer, Anne Marie Hilsden, Heather Lochmuller, Hanns Grieben, Ulrike Spuler, Simone Tesi Rocha, Carolina Day, John W Jones, Kristi J Bharucha-Goebel, Diana X Salort-Campana, Emmanuelle Harms, Matthew Pestronk, Alan Krause, Sabine Schreiber-Katz, Olivia Walter, Maggie C Paradas, Carmen Hogrel, Jean-Yves Stojkovic, Tanya Takeda, Shin’ichi Mori-Yoshimura, Madoka Bravver, Elena Sparks, Susan Bello, Luca Semplicini, Claudio Pegoraro, Elena Mendell, Jerry R Bushby, Kate Straub, Volker J Neurol Neurosurg Psychiatry Neuromuscular BACKGROUND AND OBJECTIVE: Dysferlinopathies are a group of muscle disorders caused by mutations in the DYSF gene. Previous muscle imaging studies describe a selective pattern of muscle involvement in smaller patient cohorts, but a large imaging study across the entire spectrum of the dysferlinopathies had not been performed and previous imaging findings were not correlated with functional tests. METHODS: We present cross-sectional T1-weighted muscle MRI data from 182 patients with genetically confirmed dysferlinopathies. We have analysed the pattern of muscles involved in the disease using hierarchical analysis and presented it as heatmaps. Results of the MRI scans have been correlated with relevant functional tests for each region of the body analysed. RESULTS: In 181 of the 182 patients scanned, we observed muscle pathology on T1-weighted images, with the gastrocnemius medialis and the soleus being the most commonly affected muscles. A similar pattern of involvement was identified in most patients regardless of their clinical presentation. Increased muscle pathology on MRI correlated positively with disease duration and functional impairment. CONCLUSIONS: The information generated by this study is of high diagnostic value and important for clinical trial development. We have been able to describe a pattern that can be considered as characteristic of dysferlinopathy. We have defined the natural history of the disease from a radiological point of view. These results enabled the identification of the most relevant regions of interest for quantitative MRI in longitudinal studies, such as clinical trials. CLINICAL TRIAL REGISTRATION: NCT01676077. BMJ Publishing Group 2018-10 2018-05-07 /pmc/articles/PMC6166612/ /pubmed/29735511 http://dx.doi.org/10.1136/jnnp-2017-317488 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Neuromuscular
Diaz-Manera, Jordi
Fernandez-Torron, Roberto
LLauger, Jaume
James, Meredith K
Mayhew, Anna
Smith, Fiona E
Moore, Ursula R
Blamire, Andrew M
Carlier, Pierre G
Rufibach, Laura
Mittal, Plavi
Eagle, Michelle
Jacobs, Marni
Hodgson, Tim
Wallace, Dorothy
Ward, Louise
Smith, Mark
Stramare, Roberto
Rampado, Alessandro
Sato, Noriko
Tamaru, Takeshi
Harwick, Bruce
Rico Gala, Susana
Turk, Suna
Coppenrath, Eva M
Foster, Glenn
Bendahan, David
Le Fur, Yann
Fricke, Stanley T
Otero, Hansel
Foster, Sheryl L
Peduto, Anthony
Sawyer, Anne Marie
Hilsden, Heather
Lochmuller, Hanns
Grieben, Ulrike
Spuler, Simone
Tesi Rocha, Carolina
Day, John W
Jones, Kristi J
Bharucha-Goebel, Diana X
Salort-Campana, Emmanuelle
Harms, Matthew
Pestronk, Alan
Krause, Sabine
Schreiber-Katz, Olivia
Walter, Maggie C
Paradas, Carmen
Hogrel, Jean-Yves
Stojkovic, Tanya
Takeda, Shin’ichi
Mori-Yoshimura, Madoka
Bravver, Elena
Sparks, Susan
Bello, Luca
Semplicini, Claudio
Pegoraro, Elena
Mendell, Jerry R
Bushby, Kate
Straub, Volker
Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
title Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
title_full Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
title_fullStr Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
title_full_unstemmed Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
title_short Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
title_sort muscle mri in patients with dysferlinopathy: pattern recognition and implications for clinical trials
topic Neuromuscular
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166612/
https://www.ncbi.nlm.nih.gov/pubmed/29735511
http://dx.doi.org/10.1136/jnnp-2017-317488
work_keys_str_mv AT diazmanerajordi musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT fernandeztorronroberto musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT llaugerjaume musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT jamesmeredithk musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT mayhewanna musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT smithfionae musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT mooreursular musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT blamireandrewm musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT carlierpierreg musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT rufibachlaura musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT mittalplavi musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT eaglemichelle musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT jacobsmarni musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT hodgsontim musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT wallacedorothy musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT wardlouise musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT smithmark musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT stramareroberto musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT rampadoalessandro musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT satonoriko musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT tamarutakeshi musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT harwickbruce musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT ricogalasusana musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT turksuna musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT coppenrathevam musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT fosterglenn musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT bendahandavid musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT lefuryann musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT frickestanleyt musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT oterohansel musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT fostersheryll musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT pedutoanthony musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT sawyerannemarie musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT hilsdenheather musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT lochmullerhanns musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT griebenulrike musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT spulersimone musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT tesirochacarolina musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT dayjohnw musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT joneskristij musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT bharuchagoebeldianax musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT salortcampanaemmanuelle musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT harmsmatthew musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT pestronkalan musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT krausesabine musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT schreiberkatzolivia musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT waltermaggiec musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT paradascarmen musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT hogreljeanyves musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT stojkovictanya musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT takedashinichi musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT moriyoshimuramadoka musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT bravverelena musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT sparkssusan musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT belloluca musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT sempliciniclaudio musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT pegoraroelena musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT mendelljerryr musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT bushbykate musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT straubvolker musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials
AT musclemriinpatientswithdysferlinopathypatternrecognitionandimplicationsforclinicaltrials